Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis

Assessment according to GAP Stage

Myung Jin Song, Sung Yoon Lim, Jong Sun Park, Ho Il Yoon, Jae Ho Lee, Song Yee Kim, Ji Ye Jung, youngae kang, Moo Suk Park, Young Sam Kim, Joon Chang, Sang Hoon Lee, Choon Taek Lee

Research output: Contribution to journalArticle

Abstract

Introduction. Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer development, and small cell lung cancer (SCLC) comprises 15-20% of lung cancers with IPF. The objective of this study was to investigate survival outcomes and treatment-related complications according to GAP (gender, age, and physiology) stage in patients having SCLC with IPF (SCLC-IPF). Materials and Methods. Retrospectively collected data of SCLC-IPF patients from two tertiary care university hospitals in South Korea were reviewed. A total of 59 SCLC-IPF patients were identified and categorized according to GAP stage, which was proposed by Ley et al. in 2012 to predict the prognosis of IPF. Survival outcomes and treatment-related complications were compared between the two groups. Results. In a total of 59 patients, the median age was 71 years and 58 (98.3%) were male. In a comparison of the median overall survival (OS) according to GAP stage, median OS of the advanced GAP stage group was significantly shorter than median OS of GAP stage I group (7.1 months vs. 16.1 months; p = 0.002). Treatment-related complications occurred more frequently in the advanced GAP stage group; advanced GAP stage was the only predictor that exhibited a significant association with the incidence of acute exacerbation of IPF. Conclusions. Inferior survival outcome and higher incidence of treatment-related pulmonary toxicities were noted in the advanced GAP stage group. Furthermore, advanced GAP stage was the only predictor of treatment-related acute exacerbation of IPF. Physicians should thus consider GAP stage, which reflects the severity of IPF, during treatment of SCLC-IPF.

Original languageEnglish
Article number5437390
JournalJournal of Oncology
Volume2019
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Idiopathic Pulmonary Fibrosis
Small Cell Lung Carcinoma
Survival
Lung Neoplasms
Republic of Korea
Incidence
Tertiary Healthcare
Therapeutics
Physicians
Lung

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Song, M. J., Lim, S. Y., Park, J. S., Yoon, H. I., Lee, J. H., Kim, S. Y., ... Lee, C. T. (2019). Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage. Journal of Oncology, 2019, [5437390]. https://doi.org/10.1155/2019/5437390
Song, Myung Jin ; Lim, Sung Yoon ; Park, Jong Sun ; Yoon, Ho Il ; Lee, Jae Ho ; Kim, Song Yee ; Jung, Ji Ye ; kang, youngae ; Park, Moo Suk ; Kim, Young Sam ; Chang, Joon ; Lee, Sang Hoon ; Lee, Choon Taek. / Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis : Assessment according to GAP Stage. In: Journal of Oncology. 2019 ; Vol. 2019.
@article{43500ebb281e48e8a07edc3ad7226c9f,
title = "Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage",
abstract = "Introduction. Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer development, and small cell lung cancer (SCLC) comprises 15-20{\%} of lung cancers with IPF. The objective of this study was to investigate survival outcomes and treatment-related complications according to GAP (gender, age, and physiology) stage in patients having SCLC with IPF (SCLC-IPF). Materials and Methods. Retrospectively collected data of SCLC-IPF patients from two tertiary care university hospitals in South Korea were reviewed. A total of 59 SCLC-IPF patients were identified and categorized according to GAP stage, which was proposed by Ley et al. in 2012 to predict the prognosis of IPF. Survival outcomes and treatment-related complications were compared between the two groups. Results. In a total of 59 patients, the median age was 71 years and 58 (98.3{\%}) were male. In a comparison of the median overall survival (OS) according to GAP stage, median OS of the advanced GAP stage group was significantly shorter than median OS of GAP stage I group (7.1 months vs. 16.1 months; p = 0.002). Treatment-related complications occurred more frequently in the advanced GAP stage group; advanced GAP stage was the only predictor that exhibited a significant association with the incidence of acute exacerbation of IPF. Conclusions. Inferior survival outcome and higher incidence of treatment-related pulmonary toxicities were noted in the advanced GAP stage group. Furthermore, advanced GAP stage was the only predictor of treatment-related acute exacerbation of IPF. Physicians should thus consider GAP stage, which reflects the severity of IPF, during treatment of SCLC-IPF.",
author = "Song, {Myung Jin} and Lim, {Sung Yoon} and Park, {Jong Sun} and Yoon, {Ho Il} and Lee, {Jae Ho} and Kim, {Song Yee} and Jung, {Ji Ye} and youngae kang and Park, {Moo Suk} and Kim, {Young Sam} and Joon Chang and Lee, {Sang Hoon} and Lee, {Choon Taek}",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/5437390",
language = "English",
volume = "2019",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

Song, MJ, Lim, SY, Park, JS, Yoon, HI, Lee, JH, Kim, SY, Jung, JY, kang, Y, Park, MS, Kim, YS, Chang, J, Lee, SH & Lee, CT 2019, 'Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage', Journal of Oncology, vol. 2019, 5437390. https://doi.org/10.1155/2019/5437390

Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis : Assessment according to GAP Stage. / Song, Myung Jin; Lim, Sung Yoon; Park, Jong Sun; Yoon, Ho Il; Lee, Jae Ho; Kim, Song Yee; Jung, Ji Ye; kang, youngae; Park, Moo Suk; Kim, Young Sam; Chang, Joon; Lee, Sang Hoon; Lee, Choon Taek.

In: Journal of Oncology, Vol. 2019, 5437390, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis

T2 - Assessment according to GAP Stage

AU - Song, Myung Jin

AU - Lim, Sung Yoon

AU - Park, Jong Sun

AU - Yoon, Ho Il

AU - Lee, Jae Ho

AU - Kim, Song Yee

AU - Jung, Ji Ye

AU - kang, youngae

AU - Park, Moo Suk

AU - Kim, Young Sam

AU - Chang, Joon

AU - Lee, Sang Hoon

AU - Lee, Choon Taek

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction. Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer development, and small cell lung cancer (SCLC) comprises 15-20% of lung cancers with IPF. The objective of this study was to investigate survival outcomes and treatment-related complications according to GAP (gender, age, and physiology) stage in patients having SCLC with IPF (SCLC-IPF). Materials and Methods. Retrospectively collected data of SCLC-IPF patients from two tertiary care university hospitals in South Korea were reviewed. A total of 59 SCLC-IPF patients were identified and categorized according to GAP stage, which was proposed by Ley et al. in 2012 to predict the prognosis of IPF. Survival outcomes and treatment-related complications were compared between the two groups. Results. In a total of 59 patients, the median age was 71 years and 58 (98.3%) were male. In a comparison of the median overall survival (OS) according to GAP stage, median OS of the advanced GAP stage group was significantly shorter than median OS of GAP stage I group (7.1 months vs. 16.1 months; p = 0.002). Treatment-related complications occurred more frequently in the advanced GAP stage group; advanced GAP stage was the only predictor that exhibited a significant association with the incidence of acute exacerbation of IPF. Conclusions. Inferior survival outcome and higher incidence of treatment-related pulmonary toxicities were noted in the advanced GAP stage group. Furthermore, advanced GAP stage was the only predictor of treatment-related acute exacerbation of IPF. Physicians should thus consider GAP stage, which reflects the severity of IPF, during treatment of SCLC-IPF.

AB - Introduction. Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer development, and small cell lung cancer (SCLC) comprises 15-20% of lung cancers with IPF. The objective of this study was to investigate survival outcomes and treatment-related complications according to GAP (gender, age, and physiology) stage in patients having SCLC with IPF (SCLC-IPF). Materials and Methods. Retrospectively collected data of SCLC-IPF patients from two tertiary care university hospitals in South Korea were reviewed. A total of 59 SCLC-IPF patients were identified and categorized according to GAP stage, which was proposed by Ley et al. in 2012 to predict the prognosis of IPF. Survival outcomes and treatment-related complications were compared between the two groups. Results. In a total of 59 patients, the median age was 71 years and 58 (98.3%) were male. In a comparison of the median overall survival (OS) according to GAP stage, median OS of the advanced GAP stage group was significantly shorter than median OS of GAP stage I group (7.1 months vs. 16.1 months; p = 0.002). Treatment-related complications occurred more frequently in the advanced GAP stage group; advanced GAP stage was the only predictor that exhibited a significant association with the incidence of acute exacerbation of IPF. Conclusions. Inferior survival outcome and higher incidence of treatment-related pulmonary toxicities were noted in the advanced GAP stage group. Furthermore, advanced GAP stage was the only predictor of treatment-related acute exacerbation of IPF. Physicians should thus consider GAP stage, which reflects the severity of IPF, during treatment of SCLC-IPF.

UR - http://www.scopus.com/inward/record.url?scp=85066022355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066022355&partnerID=8YFLogxK

U2 - 10.1155/2019/5437390

DO - 10.1155/2019/5437390

M3 - Article

VL - 2019

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 5437390

ER -